PPG Industries, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? PPG Industries, Inc. trades at $107.4 (market cap $24.39B), while Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 3.4× PPG Industries, Inc.'s market cap, and PPG Industries, Inc. pays the higher dividend (2.7%). Which is the better fit depends on your goals.
| PPG | REGN | |
|---|---|---|
Market Cap | $24.39B | $83.43B |
Sector | Basic Materials | Health |
52-Week High | $131.56 | $852.03 |
52-Week Low | $94.34 | $555.51 |
Enterprise Value | $30.26B | $78.14B |
Dividend Yield | 2.7% | 0.46% |
Signals from Pluang's Aura AI — not financial advice
PPG Industries trades at $109.72, down 2.5% today, with a bearish technical signal and mixed earnings history. The stock shows solid fundamentals with a P/E of 15.74, net income margin of 9.57%, and a consensus analyst price target of $129.17. Recent news highlights product innovations like the ONE RANGE marine coatings and leadership changes aimed at growth. Cash flow improved in 2025 to $893M net, though 2026 projections show a slight decline.
The outlook is cautiously optimistic, supported by analyst buy ratings (55%) and strong profitability metrics, but risks include volatile earnings performance and economic sensitivity. Near-term resistance at $111 and support at $109 are key levels to watch amid current bearish technical trends.
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Trailing returns across standard periods
Latest headlines on both assets
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →